Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lancovutide

Drug Profile

Lancovutide

Alternative Names: 2622U90; Duramycin; Moli 1901; PA 48009

Latest Information Update: 09 May 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lantibio
  • Developer AOP Orphan Pharmaceuticals AG; Lantibio
  • Class Expectorants; Peptides
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cystic fibrosis; Dry eyes

Most Recent Events

  • 16 Sep 2009 Pharmacokinetics data from a phase I trial in Cystic fibrosis presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 08 Mar 2007 Results from a phase II clinical trial in patients with Cystic fibrosis have been added to the adverse events and Respiratory disoders therapeutic trials sections
  • 17 Jan 2006 Phase-II clinical trials in Cystic fibrosis in Austria (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top